
China’s First Domestic BCMA×CD3 Bispecific Antibody Approved for Relapsed/Refractory Multiple Myeloma
China’s first domestically developed B‑cell maturation antigen×Cluster of differentiation 3 (BCMA×CD3) bispecific antibody, Vonsetamig Injection, has received official approval from the National Medical Products Administration (NMPA). The new class 1 biologic drug is indicated for adult patients with relapsed or…






